Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Cadonilimab (AK104) Plus Chemotherapy in the Treatment of Recurrent or Advanced Endometrial Cancer: a Multicenter, Prospective Phase II Trial

Next Previous
Trial Profile

Efficacy and Safety of Cadonilimab (AK104) Plus Chemotherapy in the Treatment of Recurrent or Advanced Endometrial Cancer: a Multicenter, Prospective Phase II Trial

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cadonilimab (Primary) ; Carboplatin; Cisplatin; Paclitaxel
  • Indications Adenocarcinoma; Carcinoma; Endometrial cancer
  • Focus Therapeutic Use

Most Recent Events

  • 20 Jan 2024 Planned initiation date changed from 15 Dec 2023 to 1 Feb 2024.
  • 09 Dec 2023 Treatment cycle for chemotherapy drug changed from 6-8 cycles to 6 cycles.
  • 09 Dec 2023 Planned initiation date changed from 15 Oct 2023 to 15 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top